Conjunctivitis Market Size, Share & Trends Analysis Report, By Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, and Viral Conjunctivitis), By Formulations Type (Ointment, Drops, Drugs) and By Region, And Segment Forecasts, Till : 2030

Report ID : AMR1004983 | Industries : Healthcare | Published On :January 2024 | Page Count : 208

Conjunctivitis Market Size, Share & Trends Analysis Report, By Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, and Viral Conjunctivitis), By Formulations Type (Ointment, Drops, Drugs) and By Region, And Segment Forecasts, Till – 2030

Market Overview

According to Analytical Market Research, the global Conjunctivitis market estimated at USD 4.4 billion in 2022 and will expand at a compound annual growth rate (CAGR) of 3.7% from 2023 to 2030. Key players in the Conjunctivitis market employ various strategies to maintain and enhance their market presence. These strategies help key players capture a significant market share and remain competitive in the dynamic Conjunctivitis market. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated includes proficient analysis, predictive analysis, prescriptive analysis, cumulative analysis, and value chain analysis.

Conjunctivitis MARKET DYNAMICS: KEY DRIVERS & RESTRAINTS

Increased Incidence of Conjunctivitis:
The growing incidence of conjunctivitis, commonly known as pink eye, is a significant driver for the conjunctivitis treatment market. Factors such as viral and bacterial infections, allergens, and environmental factors contribute to the rise in conjunctivitis cases. This increased prevalence propels the demand for effective and timely treatments, driving the growth of the conjunctivitis treatment market.

Limited Efficacy of Current Treatment Options:

A notable restraint in the conjunctivitis treatment market is the limited efficacy of some current treatment options. While various treatments, including antibiotics and antiviral medications, exist, the effectiveness may vary based on the causative agent and the type of conjunctivitis. Additionally, challenges such as antibiotic resistance and the need for personalized treatment strategies present obstacles to achieving universally successful outcomes, impacting the overall market growth.

How are Segments Performing in the Global Conjunctivitis Market?

Conjunctivitis Disease Type Segment Breakdown
According to Analytical Market Research, the Conjunctivitis market by Disease Type is segmented into Allergic Conjunctivitis, Bacterial Conjunctivitis, and Viral Conjunctivitis.
Conjunctivitis Formulations Type Segment Breakdown
According to Analytical Market Research, based on vehicle type, the market is segmented into Ointment, Drops, and Drugs.
Conjunctivitis Geographic Exploration
According to Analytical Market Research, the Asia-Pacific region is predicted to dominate the market, owing to the rise in the automotive industry in the region. Other regions competing in the market are North America, Europe, Middle East and Africa and Latin America respectively.

COMPETITIVE LANDSCAPE & RECENT DEVELOPMENT: Conjunctivitis

The significant players rapidly evolve with new strategies to attain a competitive edge and capture significant market share.
• For Instance, in May 2022, The National Medical Products Administration (NMPA) in China awarded Santen Pharmaceutical's legal entity authority to utilize Verkazia for the treatment of severe vernal keratoconjunctivitis (VKC) in children and adolescents aged four years and older.

Noticeable Players Functioning in The Global Conjunctivitis Market Include:

• Alembic Pharmaceuticals
• Novartis AG
• Sanofi SA
• Bausch & Lomb Incorporated
• Allergan PLC
• NicOx SA
• Sirion Therapeutics Inc
• Pfizer Inc.
• Santen Pharmaceuticals Co. Ltd.
KEY BREAKDOWN: Conjunctivitis Market
By Disease Type:
• Allergic Conjunctivitis
• Bacterial Conjunctivitis
• Viral Conjunctivitis
By Formulations Type
• Ointment
• Drops
• Drugs

Geographical Exploration:

• North America
o The USA
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o South East Asia
o Rest of Asia Pacific
• Latin America
o Brazil
o Argentina
o Rest of Latin America
• Middle East and Africa
o GCC Countries
o South Africa
o Rest of MEA

1. Research Methodology
1.1. Global Conjunctivitis Market Snapshot, 2023 and 2030
1.2. Data Mining
1.3. Validation
1.4. Primary Interviews
1.5. List of Data Sources
1.6. Future Market Projections
1.7. Industry Developments and Key Market Events
2. Executive Summary
3. Market Overview
3.1. Market Scope and Definition
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunity
3.2.4. Challenges
3.2.5. Cumulative Impact due to Recent Energy Crisis
3.2.6. Cumulative Impact due to Nearing Economic Downturn
3.2.7. Post Covid-19 World Supply & Demand Conditions
3.2.8. Cumulative Impact of Russia-Ukraine Conflict
3.2.9. Key Trends
3.3. Conjunctivitis Market: Value Chain
3.3.1. List of Raw Material Supplier
3.3.2. List of Manufacturers
3.3.3. List of Formulations Types
3.4. Porter Five Force’s Analysis
3.5. Regulatory and Technology Landscape
4. Global Conjunctivitis Market Outlook: Forecast (2023 – 2030)
4.1. Key Highlights
4.1.1. Market Size and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Current Market Size Forecast, 2023–2030
4.3. Global Conjunctivitis Market Outlook: Disease Type
4.3.1. Introduction / Key Findings
4.3.2. Market Size (US$ Mn) and Forecast Disease Type, 2023 – 2030
4.3.2.1. Allergic Conjunctivitis
4.3.2.2. Bacterial Conjunctivitis
4.3.2.3. Viral Conjunctivitis
4.4. Global Conjunctivitis Market Outlook: Formulations Type
4.4.1. Introduction / Key Findings
4.4.2. Market Size (US$ Mn) and Forecast By Formulations Type, 2023 – 2030
4.4.2.1. Ointment
4.4.2.2. Drops
4.4.2.3. Drugs
5. Global Conjunctivitis Market Outlook: Region
5.1. Key Highlights
5.2. Market Size (US$ Mn) and Forecast By Region, 2023 – 2030
5.2.1. North America
5.2.2. Europe
5.2.3. Asia Pacific
5.2.4. Latin America
5.2.5. Middle East & Africa (MEA)
6. North America Conjunctivitis Market Outlook: Forecast (2023 – 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2022
6.3.1. By Country
6.3.2. By Disease Type
6.3.3. By Formulations Type
6.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
6.4.1. U.S.
6.4.2. Canada
6.4.3. Mexico
6.5. Market Size (US$ Mn) and Forecast By Disease Type, 2023 – 2030
6.5.1. Allergic Conjunctivitis
6.5.2. Bacterial Conjunctivitis
6.5.3. Viral Conjunctivitis
6.6. Market Size (US$ Mn) and Forecast By Formulations Type, 2023 – 2030
6.6.1. Ointment
6.6.2. Drops
6.6.3. Drugs
7. Europe Conjunctivitis Market Outlook: Forecast (2023 – 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2030
7.3.1. By Country
7.3.2. By Disease Type
7.3.3. By Formulations Type
7.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
7.4.1. Germany
7.4.2. France
7.4.3. U.K.
7.4.4. Russia
7.4.5. Italy
7.4.6. Spain
7.4.7. Rest of Europe
7.5. Market Size (US$ Mn) and Forecast By Disease Type, 2023 – 2030
7.5.1. Allergic Conjunctivitis
7.5.2. Bacterial Conjunctivitis
7.5.3. Viral Conjunctivitis
7.6. Market Size (US$ Mn) and Forecast By Formulations Type, 2023 – 2030
7.6.1. Ointment
7.6.2. Drops
7.6.3. Drugs
8. Asia Pacific Conjunctivitis Market Outlook: Forecast (2023 – 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2030
8.3.1. By Country
8.3.2. By Disease Type
8.3.3. By Formulations Type
8.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. South Korea
8.4.5. Australia
8.4.6. New Zealand
8.4.7. Singapore
8.4.8. Malaysia
8.4.9. Rest of Asia
8.5. Market Size (US$ Mn) and Forecast By Disease Type, 2023 – 2030
8.5.1. Allergic Conjunctivitis
8.5.2. Bacterial Conjunctivitis
8.5.3. Viral Conjunctivitis
8.6. Market Size (US$ Mn) and Forecast By Formulations Type, 2023 – 2030
8.6.1. Ointment
8.6.2. Drops
8.6.3. Drugs
9. Latin America Conjunctivitis Market Outlook: Forecast (2023 – 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2030
9.3.1. By Country
9.3.2. By Disease Type
9.3.3. By Formulations Type
9.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Colombia
9.4.4. Peru
9.4.5. Chile
9.4.6. Venezuela
9.4.7. Rest of Latin America
9.5. Market Size (US$ Mn) and Forecast By Disease Type, 2023 – 2030
9.5.1. Allergic Conjunctivitis
9.5.2. Bacterial Conjunctivitis
9.5.3. Viral Conjunctivitis
9.6. Market Size (US$ Mn) and Forecast By Formulations Type, 2023 – 2030
9.6.1. Ointment
9.6.2. Drops
9.6.3. Drugs
10. Middle East & Africa Conjunctivitis Market Outlook: Forecast (2023 – 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2023 – 2030
10.3.1. By Country
10.3.2. By Disease Type
10.3.3. By Formulations Type
10.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
10.4.1. Saudi Arabia
10.4.2. UAE
10.4.3. Egypt
10.4.4. Kuwait
10.4.5. South Africa
10.4.6. Rest of Middle East & Africa
10.5. Market Size (US$ Mn) and Forecast By Disease Type, 2023 – 2030
10.5.1. Allergic Conjunctivitis
10.5.2. Bacterial Conjunctivitis
10.5.3. Viral Conjunctivitis
10.6. Market Size (US$ Mn) and Forecast By Formulations Type, 2023 – 2030
10.6.1. Ointment
10.6.2. Drops
10.6.3. Drugs
11. Competition Analysis
11.1. Market Share Analysis Of Top Vendors
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Dashboard
11.2.3. Key Development Strategies
11.3. Company Profiles
11.3.1. Santen Pharmaceuticals Co. Ltd
11.3.1.1. Overview
11.3.1.2. Offerings
11.3.1.3. Business Segment & Geographic Overview
11.3.1.4. Key Financials
11.3.1.5. Key Market Developments
11.3.1.6. Key Market Strategy
11.3.2. Alembic Pharmaceuticals
11.3.3. Novartis AG
11.3.4. Sanofi SA
11.3.5. Bausch & Lomb Incorporated
11.3.6. Allergan PLC
11.3.7. NicOx SA
11.3.8. Sirion Therapeutics Inc
11.3.9. Pfizer Inc..